| Literature DB >> 28443214 |
Goyitom Gebremedhn1,2, Tewelde Tesfay Gebremariam1, Araya Gebreyesus Wasihun1, Tsehaye Asmelash Dejene1, Muthupandian Saravanan1.
Abstract
HIV-positive individuals are at higher risk of Methicillin Resistant Staphylococcus aureus (MRSA) colonization and its related infection. There is limited data in the nation on the prevalence and risk factors of MRSA colonization among HIV patients. The aim of this study was to address the existing knowledge gap. Cross sectional study was carried out from September 2014 to February 2015 in three selected health centers and one general hospital. A standardized questionnaire was developed for collection of socio-demographic and clinical data. A total of 498 Nasal and throat swabs (two for each patient) were collected from 249 patients, transported and processed using standard bacteriological procedures. Data was analyzed using Chi square (X2) test and associated risk factors were determined. P < 0.05 was considered statistically significant. Out of 249 study participants, S. aureus was isolated from 81 (32.5 %) patients, with MRSA colonization rate of 6 (2.4 %). MRSA isolates were resistant to Ciprofloxacin and trimethoprim-sulphamethoxazole (16.7 % each), clindamycin (33.3 %) and erythromycin (50 %). However, all MRSA isolates were 100 % sensitive to Amikacin. History of hospitalization, percutaneous device usage, patients with a household member's hospitalization and low CD4 count (<200 cells/mm3) were significantly associated with S. aureus colonization (p < 0.05).Entities:
Keywords: CD4 count; HIV patients; MRSA; Prevalence; Risk factors; S. aureus
Year: 2016 PMID: 28443214 PMCID: PMC5396476 DOI: 10.1186/s40064-016-2613-7
Source DB: PubMed Journal: Springerplus ISSN: 2193-1801
Analysis of risk factors for Nasal and Throat colonization of S. aureus in HIV positive individuals attending HIV care service in Northern Ethiopia, September 2014–February 2015
| Variables | Frequency (%) |
| ||
|---|---|---|---|---|
| No. (%) | OR (95 % CI) | P value | ||
| Age in years | ||||
| 1–9R | 10 (4.0) | 1 (10) | NC | 0.59 |
| 10–19 | 19 (7.6) | 8 (42.1) | ||
| 20–29 | 35 (14.1) | 10 (28.6) | ||
| 30–39 | 103 (41.4) | 36 (35.0) | ||
| 40–49 | 55 (22.1) | 18 (32.7) | ||
| 50–59 | 17 (6.8) | 5 (29.4) | ||
| 60–69 | 7 (2.8) | 1 (14.3) | ||
| 70–79 | 3 (1.2) | 2 (66.7) | ||
| Sex | ||||
| FemaleR | 174 (69.9) | 62 (35.6) | 0.613 (0.334–1.123) | 0.113 |
| Male | 75 (30.1) | 19 (25.3) | ||
| Hospitalization in the past 6 months | ||||
| NoR | 223 (89.6) | 60 (26.9) | 11.41 (4.12–31.62) | 0.000 |
| Yes | 26 (10.4) | 21 (80.8) | ||
| Hospital visit in the past 12 months | ||||
| NoR | 61 (24.5) | 28 (45.9) | 0.463 (0.255–0.839) | 0.011 |
| Yes | 188 (75.5) | 53 (28.2) | ||
| Household member’s hospitalization in the past 1 year | ||||
| NoR | 224 (90) | 60 (26.8) | 14.35 (4.732–43.516) | 0.000 |
| Yes | 25 (10) | 21 (84.0) | ||
| Presence of percutaneous device in the past 1 year | ||||
| NoR | 189 (75.9) | 33 (17.5) | 18.91 (9.061–39.46) | 0.000 |
| Yes | 60 (24.1) | 48 (80.0) | ||
| Oral antibiotic usage in the past 3 months | ||||
| NoR | 181 (72.7) | 50 (27.6) | 2.195 (1.232–3.912) | 0.08 |
| Yes | 68 (27.3) | 31 (45.6) | ||
| Current use of trimethoprim-sulfamethoxazole | ||||
| NoR | 161 (64.7) | 24 (27.3) | 1.462 (0.827–2.583) | 0.192 |
| Yes | 88 (35.3) | 57 (35.4) | ||
| Most recent CD4 count | ||||
| <200R | 37 (14.9) | 21 (56.8) | 1.00 | 0.004 |
| 200–500 | 109 (43.8) | 33 (30.3) | 0.331 (0.153–0.713) | 0.005 |
| >500 | 103 (41.4) | 27 (26.2) | 0.271 (0.123–0.593) | 0.001 |
The percent (%) of S. aureus colonization is the proportion of each category
R reference category
Analysis of risk factors for nasal and throat colonization of MRSA in HIV positive individuals attending HIV care service in Northern Ethiopia, September 2014–February 2015
| Variables | Frequency (%) | MRSA colonization |
|---|---|---|
| No. (%) | ||
| Age in years | ||
| 1–9R | 10 (4.0) | 0 (0) |
| 10–19 | 19 (7.6) | 0 (0) |
| 20–29 | 35 (14.1) | 2 (5.7) |
| 30–39 | 103 (41.4) | 3 (2.9) |
| 40–49 | 55 (22.1) | 1 (1.8) |
| 50–59 | 17 (6.8) | 0 (0) |
| 60–69 | 7 (2.8) | 0 (0) |
| 70–79 | 3 (1.2) | 0 (0) |
| Sex | ||
| Female | 174 (69.9) | 6 (3.4) |
| Male | 75 (30.1) | 0 (0) |
| Hospitalization in the past 6 months | ||
| No | 223 (89.6) | 4 (1.8) |
| Yes | 26 (10.4) | 2 (7.7) |
| Hospital visit in the past 12 months | ||
| No | 61 (24.5) | 2 (3.3) |
| Yes | 188 (75.5) | 4 (2.1) |
| Household member hospitalization in the past 1 year | ||
| No | 224 (90) | 4 (1.8) |
| Yes | 25 (10) | 2 (8.0) |
| Presence of percutaneous device in the past 1 year | ||
| No | 189 (75.9) | 2 (1.1) |
| Yes | 60 (24.1) | 4 (6.7) |
| Oral antibiotic usage in the past 3 months | ||
| No | 181 (72.7) | 3 (1.7) |
| Yes | 68 (27.3) | 3 (4.4) |
| Current use of trimethoprim-sulfamethoxazole | ||
| No | 161 (64.7) | 2 (2.3) |
| Yes | 88 (35.3) | 4 (2.5) |
| Most recent CD4 count | ||
| <200 | 37 (14.9) | 3 (8.1) |
| 200–500 | 109 (43.8) | 1 (0.9) |
| >500 | 103 (41.4) | 2 (1.9) |
The percent (%) of MRSA colonization is the proportion of each category
R reference category
Multivariate analysis of independent risk factors associated with S. aureus colonization among HIV positive individuals attending HIV care service in Northern Ethiopia, September 2014–February 2015
| Risk factors | AOR (95 % CI) | P value |
|---|---|---|
| Hospitalization in the past 6 months | 9.97 (2.69–36.87) | 0.001 |
| Hospital visit in the past 12 months | 0.31 (0.14–0.697) | 0.004 |
| Presence of percutaneous device in the past 1 year | 20.695 (8.75–48.96) | 0.000 |
| Family member’s hospitalization in the past 1 year | 12.97 (3.48–48.30) | 0.000 |
| Most recent CD4 count | ||
| <200 | 0.016 | |
| 200–500 | 0.33 (0.12–0.91) | 0.033 |
| >500 | 0.22 (0.08–0.06) | 0.004 |
AOR adjusted odds ratio